Concepedia

Author

K. Hasegawa

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

K. Hasegawa, Kodai Hasegawa

17

Publications

118

Citations

3

H-Index

7

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)
KH

About

K. Hasegawa is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in oncology, cancer therapeutics, and cervical cancer.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

1

1

40

2

Obstetrics

1

1

40

3

Cancer Therapeutics

1

1

40

4

Cervical Cancer

1

1

40

5

Gynecology Oncology

1

1

40

K. Hasegawa

×

2

Publications

104

Citations

2

H-Index

YearCitations

ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer

Toon Van Gorp, David Cibula, Weiguo Lv,

Annals of Oncology

2024

64

LBA38 Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study

Domenica Lorusso, Yang Xiang, K. Hasegawa,

Annals of Oncology

2023

40

Page 1